Nuveen LLC Invests $2.57 Million in Core Laboratories Inc. $CLB

Key Points

• Nuveen LLC acquired a new position in Core Laboratories Inc., buying 171,636 shares valued at approximately $2.57 million, representing about 0.37% ownership.
• Core Laboratories has received several recent rating upgrades and downgrades, with an average rating of "Hold" and an average target price of $12.50.
• The company recently announced a quarterly dividend of $0.01, which translates to an annual yield of 0.4%.

Nuveen LLC acquired a new stake in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 171,636 shares of the oil and gas company's stock, valued at approximately $2,573,000. Nuveen LLC owned 0.37% of Core Laboratories at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of CLB. Assetmark Inc. increased its position in shares of Core Laboratories by 92.5% during the first quarter. Assetmark Inc. now owns 2,887 shares of the oil and gas company's stock valued at $43,000 after purchasing an additional 1,387 shares during the period. Tower Research Capital LLC TRC boosted its stake in Core Laboratories by 843.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,284 shares of the oil and gas company's stock valued at $57,000 after buying an additional 2,936 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Core Laboratories in the 4th quarter valued at $123,000. XTX Topco Ltd acquired a new stake in Core Laboratories in the 1st quarter valued at $155,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in Core Laboratories in the 4th quarter valued at $176,000. 97.81% of the stock is currently owned by institutional investors.

Core Laboratories Trading Up 1.9%

NYSE CLB traded up $0.22 on Friday, reaching $11.54. The company had a trading volume of 376,851 shares, compared to its average volume of 454,950. The stock's 50 day moving average is $11.45 and its 200-day moving average is $12.56. The stock has a market cap of $540.88 million, a price-to-earnings ratio of 14.95, a PEG ratio of 3.48 and a beta of 1.46. The company has a quick ratio of 1.70, a current ratio of 2.27 and a debt-to-equity ratio of 0.47. Core Laboratories Inc. has a 52 week low of $9.72 and a 52 week high of $21.83.

Core Laboratories (NYSE:CLB - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The oil and gas company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.01. The business had revenue of $130.16 million during the quarter, compared to the consensus estimate of $129.19 million. Core Laboratories had a return on equity of 14.15% and a net margin of 5.73%.The firm's revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.22 earnings per share. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. Equities analysts predict that Core Laboratories Inc. will post 0.96 earnings per share for the current year.

Core Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 25th. Shareholders of record on Monday, August 4th were paid a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Monday, August 4th. Core Laboratories's payout ratio is presently 6.45%.

Analyst Ratings Changes

Several analysts recently commented on the company. Wall Street Zen raised Core Laboratories from a "sell" rating to a "hold" rating in a research note on Saturday, July 26th. Citigroup decreased their price target on Core Laboratories from $16.00 to $13.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Zacks Research raised Core Laboratories from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Finally, Stifel Nicolaus reduced their price objective on Core Laboratories from $13.00 to $12.00 and set a "hold" rating on the stock in a research note on Wednesday, July 16th. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $12.50.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.